Today: 29 June 2026
Browse Category

NASDAQ:LI 5 December 2025 - 7 December 2025

EV Stocks Weekly Recap: Tesla’s China Bounce, Rivian Recall and Policy Shockwaves Rock the Sector (Dec 1–7, 2025)

EV Stocks Weekly Recap: Tesla’s China Bounce, Rivian Recall and Policy Shockwaves Rock the Sector (Dec 1–7, 2025)

The first week of December 2025 was anything but quiet for electric vehicle stocks. While global EV adoption is still on a long‑term upward trajectory, markets spent the week wrestling with collapsing U.S. EV sales, fresh recalls, aggressive Chinese competition, and yet more price cuts from Tesla. Below is a news-style recap of the key EV stock movers and the major forecasts and analyses that shaped sentiment between 1–7 December 2025.
7 December 2025
········
Best Chinese Stocks to Buy Now (December 2025): Tech, EVs and AI Leaders in a Rebounding Market

Best Chinese Stocks to Buy Now (December 2025): Tech, EVs and AI Leaders in a Rebounding Market

China’s stock market has quietly staged a comeback in 2025 – but it’s still trading at a discount to many global peers. That mix of recovering sentiment, low valuations and heavy policy support for “new economy” sectors is exactly why Chinese stocks are back on many investors’ radar this December. FT Markets+2Energy News+2 This article looks at the best Chinese stocks to research now, based on fresh analyst reports, macro forecasts and market data as of 5 December 2025. It focuses on companies listed in Shanghai/Shenzhen, Hong Kong and U.S. ADRs that are:
5 December 2025
···········
1 2

Stock Market Today

  • Ford (F) Slips as Recalls Weigh on Stock, Quality Scores Up
    June 29, 2026, 5:54 PM EDT. Ford Motor Company shares slipped 0.7% to $14.02, lagging behind the S&P 500's 1.7% jump and a 2.4% rise in Consumer Discretionary stocks. The automaker's J.D. Power initial-quality score improved 21% to 152 problems per 100 vehicles, leading mass-market brands, but investors saw little lift with 51 recalls so far this year. The average analyst price target is at $14.78, around 5% above where the stock now trades, with most analysts stuck at Hold. The split reaction signals many doubt recent quality gains are enough to outweigh recall issues.
Go toTop